December 19, 2025 01:09 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry!
Covid19 Vaccine
Image: Unsplash

Covid-19: clinical trials using Covaxin on children begins

| @indiablooms | Jun 11, 2021, at 02:38 am

Bengaluru/UNI: In all 30 children, aged 12-18, were administered Covaxin at Mysuru Medical College and Research Institute (MMCRI) as part of Hyderabad-based pharmaceutical major Bharat Biotech's clinical trials.

 

MMCRI is the only site selected in Karnataka for the company's paediatric trials, currently being conducted pan-India across multiple locations.

When the vaccinated kids were followed up telephonically, mild pain at the injection site was observed in 10 subjects.

No other complications were reported, according to sources.

In all, MMCRI had screened 53 children, of which 23 had to be rejected as they were ineligible for the trial, on account of either having antibodies or active infection.

According to Dr C P Nanjaraj, Dean at MMCRI, screening 50 children in each age group: 12 to 18 years, 6 to 12 years, and 2 to 6 years, said, "During screening, we shall draw blood samples for Covid IgG antibodies and nasopharyngeal swabs for RT-PCR tests.

"If IgG antibodies and RT-PCR are negative, they (children) will be eligible to get into the study.

"The study subjects (children) will be given two doses of vaccine 28 days apart, and will be followed up for six months for safety analysis."

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.